David Hodl

Head of Business Development • Invetech

David is the Head of Business Development, Cell Therapy for Invetech. Since 2018 he has lead business development in the Eastern US and Europe and product portfolio management for Invetech’s Cell Therapy business. David has over 21 years of experience in product commercialization and business development roles. Prior to joining Invetech David led the Cell Processing business unit of SynGen, commercializing equipment and single-use consumables for manufacturing cell-based therapies. He also spent eight years in a business development role with Becton Dickinson’s Corporate Innovation Center, focusing on commercialization of cell-based and next-generation sequencing technologies. David earned an MBA from North Carolina State University and a BA in biology from Linfield College.

Also Speaking

Lisa McClain-Moss

Vice President, Manufacturing • Longeveron

Barbara A. Binzak Blumenfeld

Shareholder, FDA & Biotechnology • Buchanan Ingersoll Rooney

Radmila Feldmann

Patient-Centric Supply Chain Solutions for Cell and Gene Therapies • Time:Matters

Event Info


Fun Run